Compare AbbVie Inc (ABBV) vs Campbell Soup Co. (CPB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Campbell Soup Co. — how do they compare? AbbVie Inc trades at $250 (market cap $438.19B), while Campbell Soup Co. trades at $22.78 (market cap $6.69B). The key difference: AbbVie Inc is far larger — about 65.5× Campbell Soup Co.'s market cap, and Campbell Soup Co. pays the higher dividend (6.96%). Which is the better fit depends on your goals.
| ABBV | CPB | |
|---|---|---|
Market Cap | $438.19B | $6.69B |
Sector | Health | Consumer Staples |
52-Week High | $263.58 | $34.03 |
52-Week Low | $197.38 | $20.00 |
Enterprise Value | $502.45B | $13.29B |
Dividend Yield | 2.79% | 6.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.
Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.
Campbell's stock trades at $23.05, up 2.17% with a bullish technical signal. The company shows stable revenue around $10B but faces margin pressure with net income margin at 6.12%. Recent earnings beat expectations in Q1 2026, while analyst sentiment remains cautious with only 3.45% buy ratings. The stock offers a 6.8% dividend yield, supported by positive cash flow from operations of $1.13B in 2025.
The outlook remains mixed with cost-saving initiatives and product innovation providing upside potential, but persistent margin challenges and high debt levels pose significant risks. Current valuation appears reasonable with P/E of 11.29, though weak analyst consensus suggests limited near-term catalyst for price appreciation beyond dividend income.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Campbell Soup Co.
With a history that dates back around 150 years, Campbell Soup is now a leading manufacturer and marketer of branded convenience food products, most notably soup. The firm's product assortment includes well-known brands like Campbell's, Pace, Prego, Swanson, V8, and Pepperidge Farm. Following the sale of its international snacking operations, which wrapped in calendar 2019, the firm derives nearly all of its sales from its home turf. Campbell has made a handful of acquisitions to reshape its product mix the past few years, including the tie-up with Snyder's-Lance (completed in March 2018), which enhances its exposure to the faster-growing on-trend snack food aisle, complementing its Pepperidge Farm lineup.
Read more on CPB →
